Our Business

The US and Canada make up our North American commercial division, the largest in the Group.

Sales are heavily concentrated in Companion Animal Products (CAP) and Equine, delivered through our growing field-based sales representatives, tele-sales teams and other channels such as over the counter and online.

The EMEA commercial division generates revenue directly through our own sales & marketing teams in a number of European countries and via distributors. Key markets include France, Germany, Poland, Spain and the UK.

Products are sold across all key categories of Companion Animal Products (CAP), Equine and Food producing Animal Products (FAP), as well as a range of specialist therapeutic pet diets branded Specific™.

Our Internation division is made up of two regions; Asia-Pacific (APAC) and Latin American (LATAM). Within these regions we have our own legal entities in key markets such as Australia, New Zealand, South Korea, Brazil, and Mexico, whilst also working with a number of international distribution partners.

The products sold varies significantly by country, largely due to the different rates at which the Companion Animal Product (CAP) market is developing.

The Dechra Research & Development (DRD) division represents a diverse team of colleagues spanning Product Development, Portfolio Management & Innovation, Biotherapeutics Innovation, External Innovation and Regulatory Affairs.

The product development and innovation teams are located globally. They work to identify opportunities to address unmet market needs through innovation in large and small molecules or differentiated generic products that are aligned with our global strategy.

Regulatory affairs colleagues fulfil crucial activities such as obtaining licences for our products, managing post-approval adverse event reporting, periodic product renewals and other activities required to maintain the product licences in every country that we operate.

Around half of all products sold globally are produced in-house across our seven manufacturing sites. The other half of products are managed through a strategic network of external third-party contract manufacturing organisations (CMOs).

We have an ongoing programme to bring the manufacture of key products in-house, and invest across our sites to make them best in class and build capability. We have three sites located in Europe at Skipton in the UK, Bladel in the Netherlands and Zagreb in Croatia. We also have two sites in the United States at Fort Worth, Texas and Pomona, California. A further two, smaller sites are located at Londrina, Brazil and Sydney, Australia. The Manufacturing & Supply division also manages our complex global supply network, including responsibility for our distribution centre located in Uldum, Denmark.